NCT05859048 (MAPLE-CHF) is a NA clinical trial of NT-proBNP in Heart Failure, sponsored by Cardiology Research UBC.

Who is sponsoring NCT05859048?

NCT05859048 is sponsored by Cardiology Research UBC.

What drugs are being tested in NCT05859048?

Interventions in NCT05859048: NT-proBNP, AI echocardiogram, electrocardiogram, Cardiovascular physical examination.

What condition does NCT05859048 study?

NCT05859048 studies Heart Failure.

Is NCT05859048 still recruiting?

NCT05859048 is currently recruiting now. Last updated 7 March 2024.

Last reviewed 2024-03-07 · How we verify

NCT05859048: MAPLE-CHF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Recruiting now NA Last updated 7 March 2024

What this trial tests

NA trial testing NT-proBNP in Heart Failure in 1,360 participants. Currently enrolling.

Timeline

1 March 2024

Primary endpoint
1 January 2027

1 January 2029

Quick facts

Lead sponsor	Cardiology Research UBC
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	1,360
Start date	1 March 2024
Primary completion	1 January 2027
Estimated completion	1 January 2029
Sites	3 locations across Canada

Drugs / interventions tested

NT-proBNP
AI echocardiogram
electrocardiogram
Cardiovascular physical examination

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Cardiology Research UBC

Who can join

40 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure. The main question\[s\] it aims to answer are: • will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care? Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm: SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure. Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Heart fAilure Management Program: Changing the practice by partnering primary care and specialists (CHAMP-HF).
Parent M, Leclerc J, O'Meara E, Barrette R, et al · · 2024 · cited 1× · PMID 38298468 · DOI 10.1016/j.ijcha.2023.101330

Verify or expand the search:

Other trials of NT-proBNP

Trials testing the same drug.

NCT05919342 — Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and ech · NA · recruiting
NCT04231591 — NT-proBNP Levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients · completed
NCT04049136 — NT-proBNP Levels and Obesity in Pregnancy · completed

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Cardiology Research UBC trials

Trials by the same sponsor.

NCT07369856 — Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Hear · NA · recruiting
NCT06378775 — Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery · NA · not yet recruiting
NCT06103123 — MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study · unknown
NCT04906356 — Canadian SCAD Study · recruiting
NCT03642886 — Detraining on Atrial Fibrillation · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05859048 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardiology Research UBC
Last refreshed: 7 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05859048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing